32967-15-0

Basic information

• Product Name: Benzoic acid, 2-(3-pyridinylamino)-
• CAS NO: 32967-15-0
• Molecular Formula: C12H10N2O2
• Molecular Weight: 214.224
• Mol File: 32967-15-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-(3-pyridinylamino)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-(3-pyridinylamino)-(32967-15-0)
• EPA Substance Registry System: Benzoic acid, 2-(3-pyridinylamino)-(32967-15-0)

Safety Data

• Hazardous Substances Data: 32967-15-0(Hazardous Substances Data)

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 88-67-5 2-Iodobenzoic acid 
• 626-55-1 3-Bromopyridine 
• 118-92-3 anthranilic acid 
• 118-91-2 ortho-chlorobenzoic acid 

Relevant articles and documents

Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. VI. Indazole derivatives

Synthesis and pharmacological evaluation of novel indazole derivatives are described. These compounds were found to exhibit both thromboxane A2 (TXA2) synthetase-inhibitory and bronchodilatory activities. This observation supports th

Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma

COX-2 and STAT3 are two key culprits in the glioma microenvironment. Herein, to inhibit COX-2 and block STAT3 signaling, we disclosed 27 N-anthraniloyl tryptamine compounds based on the combination of melatonin derivatives and N-substituted anthranilic acid derivatives. Among them, NP16 showed the best antiproliferative activity and moderate COX-2 inhibition. Of note, NP16 decreased the level of p-JAK2 and p-STAT3, and blocked the nuclear translocation of STAT3 in GBM cell lines. Moreover, NP16 downregulated the MMP-9 expression of BV2 cells in a co-culture system of BV2 and C6 glioma cells, abrogated the proliferative/invasive/migratory abilities of GBM cells, induced apoptosis by ROS and the Bcl-2-regulated apoptotic pathway, and induced obvious G2/M arrest in glioma cells in vitro. Furthermore, NP16 displayed favorable pharmacokinetic profiles covering long half-life (11.43 ± 0.43 h) and high blood-brain barrier permeability. Finally, NP16 effectively inhibited tumor growth, promoted the survival rate, increased the expression of E-cadherin and reduced overproduction of PGE2, MMP-9, VEGF-A and the level of p-STAT3 in tumor tissue, and improved the anxiety-like behavior in C6 glioma model. All these evidences demonstrated N-anthraniloyl tryptamine derivatives as multifunctional anti-glioma agents with high potency could drain the swamp to beat glioma.